Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Safety and Efficacy Evaluation of IM19 CAR-T Cells On CD19+ Refractory or Relapsed B-ALL Patients

Trial Profile

Safety and Efficacy Evaluation of IM19 CAR-T Cells On CD19+ Refractory or Relapsed B-ALL Patients

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 17 Jan 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs IM19 chimeric antigen receptor T cell therapy Beijing Immunochina Medical Science and Technology (Primary) ; Cyclophosphamide; Fludarabine
  • Indications B-cell leukaemia; Precursor B-cell lymphoblastic leukaemia-lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma
  • Focus Adverse reactions
  • Sponsors Beijing Immunochina Medical Science and Technology
  • Most Recent Events

    • 13 Dec 2022 Results assessing benefits of a second Allo-HSCT after CAR-T Cell therapy presented at the 64th American Society of Hematology Annual Meeting and Exposition
    • 01 Mar 2022 Results from rom 5 clinical trials (NCT03173417, NCT02546739, NCT03671460, ChiCTR-ONC-17012829, and ChiCTR1800016541) assessing Factors associated with treatment response to CD19 CAR-T therapy among a large cohort of B cell acute lymphoblastic leukemia published in the Cancer Immunology Immunotherapy
    • 01 Feb 2022 Results of a retrospective analysis assessing Cytoplasmic CD79a as a promising biomarker for B lymphoblastic leukemia follow up post CD19 CAR-T therapy published in the Leukemia and Lymphoma
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top